Long-term survival in patients with newly diagnosed primary central nervous system lymphoma treated with dexamethasone, etoposide, ifosfamide and carboplatin chemotherapy and whole-brain radiation therapy

References

• Bataille B, Delwail V, Menet E, . Primary intracerebral malignant lymphoma: report of 248 cases. J Neurosurg 2000; 92:261–266.
   PubMed Web of Science ®Google Scholar
• Tseng MY, Tu YK, Shun CT. Primary central nervous system lymphoma: a retrospective study. J Clin Neurosci 1998;5:409–412.
   PubMed Web of Science ®Google Scholar
• Shibamoto Y, Tsuchida E, Seki K, . Primary central nervous system lymphoma in Japan 1995-1999: changes from the preceding 10 years. J Cancer Res Clin Oncol 2004;130:351–356.
   PubMed Web of Science ®Google Scholar
• Quek R, Ty A, Lim ST, . Primary central nervous system lymphoma in an Asian population: a 15-year experience. Onkologie 2006;29:455–459.
   PubMed Web of Science ®Google Scholar
• Panageas KS, Elkin EB, DeAngelis LM, . Trends in survival from primary central nervous system lymphoma, 1975-1999: a population-based analysis. Cancer 2005;104:2466–2472.
   PubMed Web of Science ®Google Scholar
• Shenkier TN, Voss N, Chhanabhai M, . The treatment of primary central nervous system lymphoma in 122 immunocompetent patients: a population-based study of successively treated cohorts from the British Colombia Cancer Agency. Cancer 2005;103:1008–1017.
   PubMed Web of Science ®Google Scholar
• Hayakawa T, Takakura K, Abe H, . Primary central nervous system lymphoma in Japan—a retrospective, co-operative study by CNS-Lymphoma Study Group in Japan. J Neurooncol 1994; 19:197–215.
   PubMed Web of Science ®Google Scholar
• Deangelis LM. Current management of primary central nervous system lymphoma. Oncology (Williston Park) 1995;9:63–71; discussion 71, 75–66, 78.
   PubMedGoogle Scholar
• Nelson DF, Martz KL, Bonner H, . Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 1992;23:9–17.
   PubMed Web of Science ®Google Scholar
• Glass J, Gruber ML, Cher L, . Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J Neurosurg 1994;81:188–195.
   PubMed Web of Science ®Google Scholar
• Hiraga S, Arita N, Ohnishi T, . Rapid infusion of high-dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomas. J Neurosurg 1999;91:221–230.
   PubMed Web of Science ®Google Scholar
• O'Brien P, Roos D, Pratt G, . Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol 2000;18:519–526.
   PubMed Web of Science ®Google Scholar
• Linnebank M, Pels H, Kleczar N, . MTX-induced white matter changes are associated with polymorphisms of methionine metabolism. Neurology 2005;64:912–913.
   PubMed Web of Science ®Google Scholar
• Takasu S, Wakabayashi T, Kajita Y, . [Effectiveness of DeVIC chemotherapy for recurrent primary central nervous system lymphoma]. No Shinkei Geka 2000;28:789–794.
   PubMedGoogle Scholar
• Okamoto M, Maruyama F, Tsuzuki M, . [Salvage chemotherapy for relapsed/refractory aggressive non-Hodgkin's lymphoma with a combination of dexamethasone, etoposide, ifosfamide and carboplatin]. Rinsho Ketsueki 1994;35:635–641.
   PubMedGoogle Scholar
• Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, . WHO classification of tumours of the central nervous system. Lyon: 2007.
   Google Scholar
• Abrey LE, Batchelor TT, Ferreri AJ, . Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 2005;23:5034–5043.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. NCI Common Terminology Criteria for Adverse Events v4.0 [Internet]. 2009. Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40
   Google Scholar
• Fischer L, Thiel E, Klasen HA, . Prospective trial on topotecan salvage therapy in primary CNS lymphoma. Ann Oncol 2006; 17:1141–1145.
   PubMed Web of Science ®Google Scholar
• Kiewe P, Fischer L, Martus P, . Primary central nervous system lymphoma: monocenter, long-term, intent-to-treat analysis. Cancer 2008;112:1812–1820.
   PubMed Web of Science ®Google Scholar
• Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma: the next step. J Clin Oncol 2000;18:3144–3150.
   PubMed Web of Science ®Google Scholar
• DeAngelis LM, Seiferheld W, Schold SC, . Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 2002;20:4643–4648.
   PubMed Web of Science ®Google Scholar
• Neuwelt EA, Goldman DL, Dahlborg SA, . Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function. J Clin Oncol 1991;9:1580–1590.
   PubMed Web of Science ®Google Scholar
• Cher L, Glass J, Harsh GR, . Therapy of primary CNS lymphoma with methotrexate-based chemotherapy and deferred radiotherapy: preliminary results. Neurology 1996;46:1757–1759.
   PubMed Web of Science ®Google Scholar
• Freilich RJ, Delattre JY, Monjour A, . Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients. Neurology 1996;46:435–439.
   PubMed Web of Science ®Google Scholar
• Hoang-Xuan K, Taillandier L, Chinot O, . Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol 2003;21:2726–2731.
   PubMed Web of Science ®Google Scholar
• O'Brien PC, Roos DE, Pratt G, . Combined-modality therapy for primary central nervous system lymphoma: long-term data from a phase II multicenter study (Trans-Tasman Radiation Oncology Group). Int J Radiat Oncol Biol Phys 2006;64:408–413.
   PubMed Web of Science ®Google Scholar
• Bessell EM, Lopez-Guillermo A, Villa S, . Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments. J Clin Oncol 2002;20: 231–236.
   PubMed Web of Science ®Google Scholar
• Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H, . High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol 2003;21:4483–4488.
   PubMed Web of Science ®Google Scholar
• Abrey LE, Ben-Porat L, Panageas KS, . Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 2006;24:5711–5715.
   PubMed Web of Science ®Google Scholar
• Imashuku S, Kuriyama K, Teramura T, . Requirement for etoposide in the treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. J Clin Oncol 2001;19: 2665–2673.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Tobinai K, Oguchi M, . Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol 2009;27:5594–5600.
   PubMed Web of Science ®Google Scholar
• Lin CH, Kuo KT, Chuang SS, . Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphoma of central nervous system origin and peripheral nodal origin. Clin Cancer Res 2006;12:1152–1156.
   PubMed Web of Science ®Google Scholar
• Levy O, Deangelis LM, Filippa DA, . Bcl-6 predicts improved prognosis in primary central nervous system lymphoma. Cancer 2008;112:151–156.
   PubMed Web of Science ®Google Scholar
• Camilleri-Broet S, Criniere E, Broet P, . A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood 2006;107:190–196.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Katayama Y, Yoshino A, . Long-term remission of primary central nervous system lymphoma by intensified methotrexate chemotherapy. J Neurooncol 2003;63:87–95.
   PubMed Web of Science ®Google Scholar
• Blay JY, Conroy T, Chevreau C, . High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol 1998;16:864–871.
   PubMed Web of Science ®Google Scholar
• Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J Clin Oncol 1998;16:859–863.
   PubMed Web of Science ®Google Scholar
• Shah GD, Yahalom J, Correa DD, . Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol 2007;25: 4730–4735.
   PubMed Web of Science ®Google Scholar
• Correa DD, Rocco-Donovan M, DeAngelis LM, . Prospective cognitive follow-up in primary CNS lymphoma patients treated with chemotherapy and reduced-dose radiotherapy. J Neurooncol 2009;91:315–321.
   PubMed Web of Science ®Google Scholar